The World's Pharma Factory Is Eyeing A Bigger Share Of Global Markets [Forbes]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Forbes
Ramesh (left) and Rajeev Juneja. Nishanth Radhakrishnan for Forbes Asia This story is part of Forbes' coverage of India's Richest 2024. See the full list here India's pharma tycoons are on an expansion tear to carve out new niches beyond generic medicines and grow their global reach. A leader in low-cost drugs, India supplies 20% of the worldwide total by volume. ss Now, as companies move further into next-generation therapeutics, the country's pharmaceutical industry is likely to double to $130 billion by 2030 and more than triple to $450 billion by 2047, according to global consultancy EY-Parthenon. Mankind Pharma, controlled by billionaire brothers Ramesh and Rajeev Juneja , announced in July plans to buy Mumbai-based Bharat Serums and Vaccines for $1.6 billion from Advent International, a U.S. private equity firm. The deal, expected to be completed soon, will position Mankind as a market leader in women's health and fertility treatments, according to Mumbai-based HS
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Pulmonary Arterial Hypertension Drugs Market to Grow by USD 2.26 Billion from 2024-2028, as Rising PAH Prevalence Drives Demand with AI Redefining Market Landscape - Technavio [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target lowered by analysts at Barclays PLC from $17.40 to $17.00. They now have an "overweight" rating on the stock.MarketBeat
- Dr Reddy's Laboratories Ltd (RDY) (HY 2025) Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
RDY
Earnings
- 11/6/24 - Beat
RDY
Sec Filings
- 11/14/24 - Form 6-K
- 11/12/24 - Form 6-K
- 11/7/24 - Form 6-K
- RDY's page on the SEC website